Duration Associated with Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Digestive Diseases, researchers have found that the duration of stability is linked with overall survival in patients with advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor sorafenib.

For the study, researchers identified 269 patients with advanced hepatocellular carcinoma who were treated with sorafenib at the Kinki University Hospital in Japan between May 2009 and January 2013.

Of those 269, 158 patients' antitumor response of sorafenib were analyzed and patients were either classified as having a short period of stable disease (<3 months) or a long period of stable disease (≥3 months).

Results showed patients classified as having short stable disease had a median overall survival of 5.7 months and patients in the long stable disease had a median overall survival of 20.8 months. Patients with a complete response or a partial response had a median overall survival of 17.9 months.

The results suggest an association between patients who have a long duration of stable disease and overall survival.

A Closer Look at Two CommonTypes of Skin Cancer
Duration of stability linked with overall survival when treated with the tyrosine kinase inhibitor sorafenib.
This study aimed to clarify the correlation between stable disease (SD) periods and overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib. Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs